Rybelsus vs. Farxiga

See how Rybelsus and Farxiga compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Rybelsus is a once-daily oral GLP-1 that lowers blood sugar and reduces cardiovascular risk in type 2 diabetes, while Farxiga is a once-daily SGLT2 inhibitor also approved for heart failure and chronic kidney disease.

  • Rybelsus commonly causes nausea and other GI side effects, while Farxiga more often causes genital and urinary infections.

  • Rybelsus needs a step-up dosing schedule over two months, while Farxiga uses a flat dose from day one.

Rybelsus vs. Farxiga Drug Summary

Rybelsus

Rybelsus (semaglutide) is an oral GLP-1 receptor agonist used to control blood sugar in adults with type 2 diabetes and to lower cardiovascular risk in those with existing heart disease. It is taken once daily, starting at 3 mg and increasing over several weeks to a maintenance dose of 7 mg or 14 mg. Some clinicians prescribe it off-label for weight loss.

Farxiga

Farxiga (dapagliflozin) is an oral SGLT2 inhibitor used to control blood sugar in type 2 diabetes, and separately approved to treat heart failure and slow chronic kidney disease progression. It is taken once daily at a fixed dose of 5 mg or 10 mg, with no titration needed. It works by causing the kidneys to remove excess glucose through urine.

Rybelsus vs. Farxiga Side Effects

Rybelsus

Most common
nausea (up to 20%)
abdominal pain (up to 11%)
diarrhea (up to 10%)
decreased appetite (up to 9%)

Farxiga

Most common
Female genital mycotic infections (6.9%)
nasopharyngitis (6.3%)
Urinary tract infections (4.3%)
back pain (4.2%)

Rybelsus vs. Farxiga Dosage

Rybelsus

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 3 mg once daily Days 1-30
Maximum dose 14 mg once daily Day 61 onward
Dose changes 2 increases Every 30 days

Farxiga

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 10 mg once daily If needed
Dose changes 1 increase As tolerated

Rybelsus vs. Farxiga Indications

Rybelsus

Rybelsus is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of heart attack, stroke, or cardiovascular death in those with established heart disease. It is not approved for type 1 diabetes or for chronic weight management, though some doctors prescribe it off-label for weight loss.

  • Blood sugar control in type 2 diabetes

  • Reduces risk of major cardiovascular events

  • Off-label use for weight loss

  • Not approved for type 1 diabetes

Farxiga

Farxiga is FDA-approved for blood sugar control in type 2 diabetes, including children 10 and older, and for reducing hospitalization risk from heart failure. It is also approved to treat heart failure directly and to slow the progression of chronic kidney disease, independent of diabetes status.

  • Blood sugar control in type 2 diabetes

  • Heart failure treatment, with or without diabetes

  • Slows chronic kidney disease progression

  • Approved for children 10 and older

Rybelsus vs. Farxiga Pros and Cons

Rybelsus

Rybelsus offers GLP-1 benefits in pill form, appealing to people who want to avoid injections. It carries a boxed warning for thyroid tumors seen in animal studies and is not appropriate for anyone with a personal or family history of certain thyroid cancers.

Pros

  • Oral tablet, no injection needed

  • Also lowers cardiovascular risk in type 2 diabetes

  • Often used off-label for weight loss

  • Same active ingredient as injectable Ozempic

Cons

  • Common GI side effects like nausea and diarrhea

  • Boxed warning for thyroid C-cell tumors

  • Not for those with history of MTC or MEN2

  • Roughly $998 to $1,029 per month without insurance

Farxiga

Farxiga has a broader label than most diabetes drugs, covering heart failure and chronic kidney disease even in people without diabetes. It requires no dose titration, but it does carry risks tied to how it works, including genital infections and volume depletion.

Pros

  • Approved for heart failure independent of diabetes

  • Also slows chronic kidney disease progression

  • Simple flat dosing with no titration period

  • Roughly $400 to $785 per month without insurance

Cons

  • Genital yeast infections are common

  • Risk of ketoacidosis even with normal blood sugar

  • Not recommended in severe kidney impairment

  • Risk of volume depletion and low blood pressure

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.